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Yasuo Kohjimoto1 and Isao Hara1Abstract
The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients
with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy.
Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients
were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months.
Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen
(ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained
BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups
(P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group.
While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low
baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower
baseline BMD.
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Bone mineral densityIntroduction
Androgen deprivation therapy (ADT) is a standard op-
tion for patients with prostate cancer (PCa) who require
systemic therapy. While ADT is effective for PCa, this
therapy can induce several side effects (Ahmadi &
Daneshmand 2013). For example, long-term ADT can
lead to decrease bone mineral density (BMD), a surro-
gate for fracture risk. Moreover, skeletal fractures are
negative predictors of overall survival in patients with
PCa (Oefelein et al. 2002). Although the clinical guide-
lines of the National Comprehensive Cancer Network
and the European Association of Urology recommend
regular BMD measurement in men with PCa undergoing
long-term ADT (NCCN Clinical Practice Guidelines in
OncologyTM. Prostate cancer [online]; EAU Guidelines* Correspondence: n_zawajp@yahoo.co.jp
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in any medium, provided the original work is pon Prostate Cancer [online]), few patients receiving
ADT actually undergo BMD testing (Morgans et al.
2013; Nadler et al. 2013). Several randomized controlled
trials demonstrated that zoledronic acid (ZA) in-
creased BMD in men with PCa who were receiving
ADT (Smith et al. 2003; Ryan et al. 2006; Michaelson
et al. 2007; Israeli et al. 2007; Satoh et al. 2009; Casey
et al. 2010; Kapoor et al. 2011; Kachnic et al. 2013;
Lang et al. 2013). Since combined androgen blockade
(CAB) prolonged overall survival in patients with PCa
without bone metastasis in comparison to gonadotropin-
releasing hormone agonist (GnRH) monotherapy (Akaza
et al. 2009), we have adapted CAB for first-line ADT. CAB
was reported to affect bone-turnover marker levels when
compared with castration alone (Yamada et al. 2008).
However, no studies have investigated the effect of ZA on
BMD in patients treated with CAB for ADT. Hence, we
evaluated the effect of a single infusion of ZA on BMD in
patients with PCa receiving CAB as first-line ADT.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Study participants
This prospective randomized trial was performed in the
Department of Urology at Wakayama Medical University
between July 2009 and August 2013. This study was ap-
proved by the Institutional Review Board of Wakayama
Medical University (No. 585). All patients between 60
and 80 years of age who had PCa without bone metasta-
sis and who didn’t receive ADT previously were candi-
dates for this study. Bone metastasis was evaluated by
radionuclide bone scan before ADT. All patients had an
Eastern Cooperative Oncology Group performance sta-
tus of 0 to 2. Patients were excluded from study if they
had scoliosis, osteosclerosis of the lumbar spine, any
other spinal diseases, calcification of abdominal aorta,
pulpal or periapical infections, history of other malig-
nancy within 5 years, or more than 1.5 times of the
upper limit of serum creatinine, aspartate aminotransfer-
ase (AST), or alanine aminotransferase (ALT). Patients
were also excluded if they had previously received ADT
or bisphosphonates within the preceding 12 months and
if they had received estrogens, calcitonin, vitamin D, iprifla-
vone, raloxifene hydrochloride, or any other drug known
to affect the skeleton within 4 weeks of randomization.
The 42 patients to meet all criteria were randomly assigned
to receive either ZA (ZA-treated group; n = 21) or no treat-
ment (control group; n = 21). At the screening visit, BMD
of the posteroanterior lumbar spine (L2-L4) was deter-
mined by dual-energy x-ray absorptiometry (DXA), and
the T-score was calculated. All patients provided written
informed consent.Study design
The study was a prospective randomized trial to deter-
mine whether a single infusion of ZA could prevent a
decrease in BMD in men with PCa without bone metas-
tasis who were receiving CAB. Patients were randomized
to receive 4-mg of ZA intravenously on day 1 only or no
treatment. Patients were allocated considering the lumbar
T-score, age, and performance status. Patients in both
groups started treatment with a GnRH agonist (leuprorelin
acetate) plus an antiandrogen (bicalutamide), and these
drugs were continued throughout the study. A 500-mg cal-
cium supplement and a multivitamin containing 400 to
800 IU of vitamin D were recommended once daily during
the study. Patients were evaluated at baseline and at
3, 6, 9, and 12 months after initiation of therapy. Bone-
turnover markers, including serum type I collagen cross-
linked N-telopeptide (NTX), serum C-telopeptide of type
I collagen (ICTP), and serum bone-specific alkaline phos-
phatase (BAP), were measured at baseline and at 6 and
12 months. BMD was measured at baseline and at
12 months.Study end points
The primary end point was the change in lumbar spine
(L2–L4) BMD from baseline to 12 months, and the sec-
ondary end points were skeletal related events (SRE) and
the change in bone-turnover markers from baseline to 6
and 12 months.
Safety assessment
Serum creatinine and calcium were measured at baseline
and monitored every 3 months. The occurrence of adverse
events (AEs) was evaluated every 3 months and was re-
corded using the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0.
Statistical analysis
This trial was designed with 80% power and a two-sided
t-test with α = 0.05 to detect a difference of 3.3% yearly
in the lumbar spine BMD between the ZA-treated group
and the control group (Smith et al. 2001). Based on
these parameters and allowing for a 15% dropout rate, a
sample size of 40 men (20 per group) was calculated.
The means ± standard deviations were recorded for con-
tinuous variables. Differences in variables between two
groups with continuous distribution, categorical distri-
bution, and ordinal parameters were assessed using Stu-
dent’s t-test, chi-square test and Mann–Whitney U-test,
respectively. Changes in BMD and biochemical markers
were analyzed by the paired t-test. The correlation
among variables was analyzed using Pearson correlation.
All analyses were performed at the 5% significance level
using StatMate IV (ATMS Co., Ltd., Tokyo, Japan).
Results
Patient characteristics
Of the 42 patients in the two groups, two patients
treated with ZA didn’t present for follow-up DXA
scan at 1 year after infusion of ZA. A total of 40 pa-
tients (ZA: n = 19, control: n = 21) were included in
the analysis on BMD. All patients were receiving a
GnRH agonist and oral bicalutamide at study entry
with continuation throughout the 12-month study
period. Baseline characteristics including age, strategy
of ADT, clinical stage, Gleason score, pretreatment
prostate-specific antigen, BMD, and biomarkers of bone-
turnover were similar when comparing both groups
(Table 1).
BMD
At 1 year after treatment, patients on ZA maintained their
T-score (P = 0.74), while control patients experienced a sig-
nificant decrease in T-score (−3.9%, P = 0.001). Change in
T-score from baseline differed significantly between the
two groups (P = 0.009) (Figure 1). We performed analysis
as stratified by baseline T-score, since the decrease in BMD
Table 1 Patient characteristics (n = 40)
Zoledronic acid Control P value
No. of patients treated 19 21
Age (years) 72.9 ± 4.8 73.4 ± 5.2 0.75
Strategy of ADT
First-line therapy 12 16 0.37
Salvage therapy 7 5
T-stage





N0 15 18 0.59
N1 4 3
Gleason score
≤6 2 3 0.25
7 5 9
≥8 12 9
Pretreatment PSA (ng/ml) 76 ± 159 37 ± 72 0.33
BMD (g/cm2) 1.235 ± 0.21 1.182 ± 0.22 0.45
T-score 0.55 ± 2.04 0.05 ± 1.91 0.46
Biomarker of bone turnover
Serum NTX (nmolBCE/L) 15.27 ± 4.86 16.13 ± 5.30 0.62
Serum ICTP (ng/ml) 4.02 ± 1.71 4.40 ± 1.65 0.48
Serum BAP (U/L) 11.57 ± 2.85 13.35 ± 4.29 0.13
ADT, androgen deprivation therapy; PSA, prostate-specific antigen; BMD, bone
mineral density; NTX, cross-linked N-telopeptide of type I collagen; ICTP,
C-telopeptide of type I collagen; BAP, bone-specific alkaline phosphatse.
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among patients with lower BMD at baseline. In ZA-treated
patients, the lower baseline T-score group (T- score ≤0;
n = 6) tended to have an increase in T-score when com-
pared with the normal baseline T-score group (T-score >0;(a)
Figure 1 Change in T-score in the ZA-treated and control groups. (a)
change in T-score from baseline in the two groups. SE, standard error of thn = 13) (P= 0.06), while no difference was revealed in con-
trol patients when comparing the lower and normal baseline
T-score group (P = 0.57) (Figure 2a). An inverse correlation
was demonstrated between baseline and change in T-score
in ZA-treated patients (r=−0.49, P= 0.03). By contrast, these
variables didn’t correlate with one another in the control
patients (r= 0.11, P= 0.61) (Figure 2b).
Bone-turnover markers
The change in Serum ICTP and serum BAP at 6 and
12 months were higher in the control group than in the
ZA-treated group. However, there was no difference in
serum NTX at 6 and 12 months when comparing the two
groups (Figure 3a). When stratified according to baseline
T-score, in the lower T-score group (T-score ≤0; n = 6)
ZA tended to prevent increase in serum NTX compared
with control, but this difference didn’t reach the level
of statistical significance (P = 0.09 and 0.07 at 6 and
12 months, respectively). In the normal T-score group
(T-score >0, n = 13), there was no difference in serum
NTX when comparing ZA-treated patients and control
(P = 0.98 and 0.88 at 6 and 12 months, respectively)
(Figure 3b). ZA treatment resulted in inhibition of a sig-
nificant increase in serum NTX at 6 months in the lower
baseline T-score group when compared with the normal
baseline T-score group (P = 0.72 and 0.01 in the lower and
normal T-score group, respectively) (Figure 3b).
Adverse events
There were no AEs higher than grade 3. Neither renal
failure nor osteonecrosis of the jaw was reported in ZA-
treated patients.
Discussion
The present study demonstrated that a single infusion of
ZA at the time of initiation of CAB for ADT resulted in
maintenance of BMD of the lumbar spine in men with
PCa without bone metastasis. Although previous several(b)
T-score at baseline and 12 months in each group; (b) Mean ± SE
e mean; ZA, zoledronic acid; Ctrl, control.
(a) (b)
Figure 2 Change in T-score, as stratified by baseline T-score. (a) Mean ± SE, as stratified by baseline T-score (T-score ≤0 vs. >0) in each group;
(b) Correlation between change in T-score and baseline T-score. SE, standard error of the mean; ZA, zoledronic acid; Ctrl, control.
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patients treated with ADT (Smith et al. 2003; Ryan et al.
2006; Michaelson et al. 2007; Israeli et al. 2007; Satoh
et al. 2009; Casey et al. 2010; Kapoor et al. 2011; Kachnic
et al. 2013; Lang et al. 2013), none of the studies(b)
(a)
Figure 3 Comparison of bone-turnover marker levels (mean ± SE). (a)
groups at baseline and at 6 and 12 months; (b) Comparison of serum NTX
the mean; NTX, cross-linked N-telopeptide of type I collagen; ICTP, C-telope
zoledronic acid; Ctrl, control.investigated men receiving CAB. Non-steroidal antiandro-
gen monotherapy maintains BMD (Sieber et al. 2004) via
maintenance of circulating testosterone levels, elevation of
estradiol levels (Smith et al. 2004), and enhancement of
osteoblast androgen receptors that act as estrogen receptorSerum NTX, ICTP, and BAP were assessed in the ZA-treated and control
levels, as stratified by baseline T-score (≤0 vs. >0). SE, standard error of
ptide of type I collagen; BAP, bone-specific alkaline phosphatase; ZA,
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bone metabolism via a decrease in bone-turnover markers
when compared with castration alone (Yamada et al. 2008).
The optimal interval and timing of ZA administration
is not clear. Other studies used ZA every 3 months
(Smith et al. 2003; Ryan et al. 2006; Israeli et al. 2007;
Casey et al. 2010; Kapoor et al. 2011). Meanwhile, a sin-
gle infusion of ZA at the time of initiation of ADT has
also been shown to prevent BMD decrease at 1-year
after ADT initiation (Michaelson et al. 2007; Satoh et al.
2009), and we confirmed this result in the present study.
Rodrigues et al. investigated the optimal schedule of ZA
administration in men with PCa undergoing ADT and
showed no differences in the change in BMD among
four 1-, 2-, 3-, or 6-month ZA intervals (Rodrigues et al.
2010). Hence, only infrequent ZA may be needed for
maintenance of BMD in men receiving ADT, which
might also extend the benefits of a decreased incidence
of severe AEs. Several studies of the timing of initiation
of ZA have suggested that early administration of ZA in
conjunction with ADT initiation could improve BMD
status (Casey et al. 2010; Lang et al. 2013) and that the
risk of bone loss is highest during the first year of ADT
(Morote et al. 2006). However, delayed ZA treatment also
provided some increase in BMD (Bhoopalam et al. 2009).
Several bone-turnover markers have been used to
monitor bone metabolism. Since serum levels of bone
markers reflect bone resorption and are comparable or
superior to conventional urinary markers that have
higher biologic variability (Woitge et al. 1999), we used
serum bone resorption markers in this study. ICTP was
shown to represent pathological bone resorption via
rapid breakdown of type I collagen and has been con-
firmed as an independent predictor of fracture (Meier
et al. 2005) and mortality among PCa patients (Jung
et al. 2011). However, ICTP didn’t reflect changes in
BMD during anti-resorptive therapy (Garnero et al.
1994). In contrast, the skeletal response to alendronate
is more apparent when evaluated with another resorptive
marker, NTX, suggesting NTX might be a better surrogate
therapeutic marker for osteoporosis (Garnero et al. 1994).
In the current study, we showed that ZA prevented the
increase in ICTP during ADT when compared with the
control, which indicates that ZA inhibited pathological
bone-turnover. We couldn’t demonstrate the effect of ZA
on NTX. However, when restricted to patients with low
baseline T-score, we confirmed that ZA tended to prevent
an increase in the therapeutic marker, NTX, and actually
induced improvement in BMD as a therapeutic effect. Fur-
thermore, in the ZA group, there was continuous inverse
correlation between baseline T-score and change in
T-score (Figure 2b, r = −0.49, P = 0.03), suggesting patients
with lower baseline T-score retain great benefits from ZA
treatment. Israeli et al. also reported patients with lowbaseline T-score experienced greater skeletal response to
ZA than those with normal T-score. (Israeli et al. 2007).
However, they only compared between two arbitrary
groups (baseline T-score ≤ −1 vs. > − 1), and in view of this,
we appropriately reaffirmed the correlation between base-
line T-score and BMD change in response to ZA treatment
among men receiving ADT. Since patients with low base-
line T-score include those who are at risk of fracture, ZA
provides great benefit especially in those with low BMD.
Skeletal strength depends on other factors in addition
to BMD, and some studies didn’t find significant correl-
ation between BMD and bone-turnover markers. The
rate of bone remodeling is a significant factor for bone
strength, and bone-turnover markers are independent
predictors of fracture (Meier et al. 2005). We should
recognize the clinical role of BMD and each bone-turnover
marker as above for appropriate bone management.
This study had some limitations. First, the sample size
was small and the study period was only 1 year. Second,
we studied only one dosing regimen, and BMD was
measured only in the lumbar spine. Additional analysis
is needed to evaluate the long-term effect of ZA in men
receiving ADT.
Conclusion
ZA administration was safe and well tolerated. A single
infusion of ZA prevented a decrease in BMD at 1-year
in men without bone metastasis who were receiving
CAB. The effect was even great in patients with low
baseline BMD.
Competing interests
The authors declare that they have no conflicts of interests.
Authors’ contributions
SN: Data collection, Data analysis, Manuscript writing. TI: Project
development, Data collection. AI: Data collection. KK: Data collection.
YK: Data collection. NM: Data collection. YK: Data collection. IH: Project
development, Manuscript editing. All authors read and approved the final
manuscript.
Author details
1Department of Urology, Wakayama Medical University School of Medicine,
811-1 Kimiidera, Wakayama 641-8509, Japan. 2Department of Urology, Rinku
General Medical Center, Osaka, Japan. 3Department of Urology, Kinan
Hospital, Wakayama, Japan.
Received: 17 July 2014 Accepted: 30 September 2014
Published: 8 October 2014
References
Ahmadi H, Daneshmand S (2013) Androgen deprivation therapy evidence-based
management of side effects. BJU Int 111:543–548, doi:10.1111/j.1464-
410X.2012.11774.x
Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y (2009)
Combined androgen blockade with bicalutamide for advanced prostate
cancer: long-term follow-up of a phase 3, double-blind, randomized study
for survival. Cancer 115:3437–3445, doi:10.1002/cncr.24395
Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van
Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H (2009) Intravenous
ZA to prevent osteoporosis in a veteran population with multiple risk factors
Nishizawa et al. SpringerPlus 2014, 3:586 Page 6 of 6
http://www.springerplus.com/content/3/1/586for bone loss on androgen deprivation therapy. J Urol 182:2257–2264,
doi:10.1016/j.juro.2009.07.046
Casey R, Gesztesi Z, Rochford J (2010) Long term ZA during androgen blockade
for prostate cancer. Can J Urol 17:5170–5177
Draper MW (2003) The role of selective estrogen receptor modulators (SERMs) in
postmenopausal health. Ann N Y Acad Sci 997:373–377
EAU Guidelines on Prostate Cancer [online] http://www.uroweb.org/gls/pdf/
09_Prostate_Cancer_LR.pdf
Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new
biochemical markers of bone turnover in late postmenopausal osteoporotic
women in response to alendronate treatment. J Clin Endocrinol Metab
79:1693–1700
Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran
DN, Warsi GM, Lacerna LV (2007) The effect of ZA on bone mineral density in
patients undergoing androgen deprivation therapy. Clin Genitourin Cancer
5:271–277
Jung K, Miller K, Wirth M, Albrecht M, Lein M (2011) Bone turnover markers as
predictors of mortality risk in prostate cancer patients with bone metastases
following treatment with ZA. Eur Urol 59:604–612, doi:10.1016/j.
eururo.2010.12.006
Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid
A, Lawton CA (2013) RTOG 0518: randomized phase III trial to evaluate ZA for
prevention of osteoporosis and associated fractures in prostate cancer
patients. Prostate Cancer Prostatic Dis 16:382–386, doi:10.1038/pcan.2013.35
Kapoor A, Gupta A, Desai N, Ahn H (2011) Effect of ZA on bone mineral density
in men with prostate cancer receiving gonadotropin-releasing hormone
analog. Prostate Cancer doi:10.1155/2011/176164
Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ,
Wilding G, Liu G, Malkovsky M, McNeel DG (2013) A randomized phase II trial
evaluating different schedules of ZA on bone mineral density in patients
with prostate cancer beginning androgen deprivation therapy. Clin
Genitourin Cancer 11:407–415, doi:10.1016/j.clgc.2013.04.029
Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA (2005) Bone resorption and
osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology
study. J Bone Miner Res 20:579–587
Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA,
Finkelstein JS, Smith MR (2007) Randomized controlled trial of annual ZA to
prevent gonadotropin-releasing hormone agonist-induced bone loss in men
with prostate cancer. J Clin Oncol 25:1038–1042
Morgans AK, Smith MR, O'Malley AJ, Keating NL (2013) Bone density testing
among prostate cancer survivors treated with androgen-deprivation therapy.
Cancer 119:863–870, doi:10.1002/cncr.27830
Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo
G, Reventos J (2006) Bone mineral density changes in patients with prostate
cancer during the first 2 years of androgen suppression. J Urol 175:1679–1683
Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis
knowledge, health beliefs, and healthy bone behaviours in patients on
iandrogen-deprivation therapy (ADT) for prostate cancer. BJU Int 111:1301–1309,
doi:10.1111/j.1464-410X.2012.11777.x
NCCN Clinical Practice Guidelines in OncologyTM. Prostate cancer [online]
http://www.nccn.org/proffesionals/physician_gls/pdf/prostate.pdf
Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures
negatively correlate with overall survival in men with prostate cancer. J Urol
168:1005–1007
Rodrigues P, Meler A, Hering F (2010) Titration of dosage for the protective effect
of ZA on bone loss in patients submitted to androgen deprivation therapy
due to prostate cancer: a prospective open-label study. Urol Int 85:180–185,
doi:10.1159/000314524
Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV (2006) ZA initiated during the
first year of androgen deprivation therapy increases bone mineral density in
patients with prostate cancer. J Urol 176:972–978
Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M,
Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of ZA to prevent
androgen deprivation therapy-induced bone loss in men with hormone-
naive prostate carcinoma. Cancer 115:3468–3474, doi:10.1002/cncr.24404
Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S (2004) Bicalutamide
150 mg maintains bone mineral density during monotherapy for localized or
locally advanced prostate cancer. J Urol 171:2272–2276
Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA,
Kantoff PW, Finkelstein JS (2001) Pamidronate to prevent bone loss during
androgen deprivation therapy for prostate cancer. N Engl J Med 345:948–955Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003)
Randomized controlled trial of ZA to prevent bone loss in men receiving
androgen deprivation therapy for nonmetastatic prostate cancer. J Urol
169:2008–2012
Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate
cancer: effects on bone mineral density and body composition. J Clin Oncol
22:2546–2553
Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ (1999)
Novel serum markers of bone resorption: clinical assessment and comparison
with established urinary indices. J Bone Miner Res 14:792–801
Yamada Y, Takahashi S, Fujimura T, Nishimatsu H, Ishikawa A, Kume H, Tomita K,
Takeuchi T, Kitamura T (2008) The effect of combined androgen blockade on
bone turnover and bone mineral density in men with prostate cancer.
Osteoporos Int 19:321–327
doi:10.1186/2193-1801-3-586
Cite this article as: Nishizawa et al.: Zoledronic acid prevents decreases
in bone mineral density in patients with prostate cancer undergoing
combined androgen blockade. SpringerPlus 2014 3:586.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
